# Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)

> **NCT05930808** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 46 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** First Test Concor (Fasted)
- **DRUG:** First Reference Concor (Fasted)
- **DRUG:** First Test Concor (Fed)
- **DRUG:** First Reference Concor (Fed)

## Key facts

- **NCT ID:** NCT05930808
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-28
- **Primary completion:** 2023-06-18
- **Final completion:** 2023-06-18
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930808, "Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05930808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*